64 results on '"Yao, Li-Chin"'
Search Results
2. A novel tumor-bearing humanized mouse model for evaluating the efficacy and predictive safety of bispecific T cell engager
3. Creation of PDX-Bearing Humanized Mice to Study Immuno-oncology
4. Abstract 5189: Comparisons of Rituximab and CD19xCD3 BiTE antitumor response across multiple humanized NSG strains engrafted with human hematopoietic stem cells
5. Table S1, Table S3, Figures S1-S8 from Characterization of the Selective Indoleamine 2,3-Dioxygenase-1 (IDO1) Catalytic Inhibitor EOS200271/PF-06840003 Supports IDO1 as a Critical Resistance Mechanism to PD-(L)1 Blockade Therapy
6. Table S1, Table S3, Figures S1-S8 from Characterization of the Selective Indoleamine 2,3-Dioxygenase-1 (IDO1) Catalytic Inhibitor EOS200271/PF-06840003 Supports IDO1 as a Critical Resistance Mechanism to PD-(L)1 Blockade Therapy
7. Data from Characterization of the Selective Indoleamine 2,3-Dioxygenase-1 (IDO1) Catalytic Inhibitor EOS200271/PF-06840003 Supports IDO1 as a Critical Resistance Mechanism to PD-(L)1 Blockade Therapy
8. Supplementary Methods from Characterization of the Selective Indoleamine 2,3-Dioxygenase-1 (IDO1) Catalytic Inhibitor EOS200271/PF-06840003 Supports IDO1 as a Critical Resistance Mechanism to PD-(L)1 Blockade Therapy
9. Supplementary Methods from Characterization of the Selective Indoleamine 2,3-Dioxygenase-1 (IDO1) Catalytic Inhibitor EOS200271/PF-06840003 Supports IDO1 as a Critical Resistance Mechanism to PD-(L)1 Blockade Therapy
10. Table S2 from Characterization of the Selective Indoleamine 2,3-Dioxygenase-1 (IDO1) Catalytic Inhibitor EOS200271/PF-06840003 Supports IDO1 as a Critical Resistance Mechanism to PD-(L)1 Blockade Therapy
11. Table S2 from Characterization of the Selective Indoleamine 2,3-Dioxygenase-1 (IDO1) Catalytic Inhibitor EOS200271/PF-06840003 Supports IDO1 as a Critical Resistance Mechanism to PD-(L)1 Blockade Therapy
12. Data from Characterization of the Selective Indoleamine 2,3-Dioxygenase-1 (IDO1) Catalytic Inhibitor EOS200271/PF-06840003 Supports IDO1 as a Critical Resistance Mechanism to PD-(L)1 Blockade Therapy
13. Data from VEGF and c-Met Blockade Amplify Angiogenesis Inhibition in Pancreatic Islet Cancer
14. Data from VEGF and c-Met Blockade Amplify Angiogenesis Inhibition in Pancreatic Islet Cancer
15. Supplementary Methods from VEGF and c-Met Blockade Amplify Angiogenesis Inhibition in Pancreatic Islet Cancer
16. Supplementary Methods from VEGF and c-Met Blockade Amplify Angiogenesis Inhibition in Pancreatic Islet Cancer
17. Supplementary Figure Legends 1-2 from VEGF and c-Met Blockade Amplify Angiogenesis Inhibition in Pancreatic Islet Cancer
18. Supplementary Figure 2 from VEGF and c-Met Blockade Amplify Angiogenesis Inhibition in Pancreatic Islet Cancer
19. Supplementary Table 1 from VEGF and c-Met Blockade Amplify Angiogenesis Inhibition in Pancreatic Islet Cancer
20. Supplementary Figure Legends 1-2 from VEGF and c-Met Blockade Amplify Angiogenesis Inhibition in Pancreatic Islet Cancer
21. Supplementary Figure 1 from VEGF and c-Met Blockade Amplify Angiogenesis Inhibition in Pancreatic Islet Cancer
22. Supplementary Figure 1 from VEGF and c-Met Blockade Amplify Angiogenesis Inhibition in Pancreatic Islet Cancer
23. Supplementary Table 1 from VEGF and c-Met Blockade Amplify Angiogenesis Inhibition in Pancreatic Islet Cancer
24. Supplementary Figure 2 from VEGF and c-Met Blockade Amplify Angiogenesis Inhibition in Pancreatic Islet Cancer
25. 1427 Comparative analysis of human immune subsets and Rituximab antitumor response across multiple NSG strains engrafted with human hematopoietic stem cells
26. 1250 A novel in vivo PBMC humanized mouse platform for long-term analysis of efficacy and toxicity of T cell-based immunotherapy drugs
27. Enhanced development of functional human NK cells in NOD‐scid‐IL2rgnull mice expressing human IL15
28. Abstract 2875: Development of a new tumor-bearing humanized mouse model to evaluate the efficacy and toxicity of bispecific T cell engagers
29. Abstract 1640: Enhanced development of functional human innate immune cells in a novel FLT3nullNSG mouse strain expressing human FLT3L
30. Abstract 1338: Humanized mouse model for in vivo evaluation of bispecific antibody efficacy
31. Plasticity of Airway Lymphatics in Development and Disease
32. Abstract 5619: PBMC humanized NSG-(KbDb)null (IA)null mouse model to evaluate immune-oncology drug efficacy
33. Abstract 5186: Human stem cell humanized mouse model for in vivo evaluation of bispecific antibody efficacy and drug-induced cytokine release
34. Abstract 3354: Preclinical evaluation of potential cytokine release syndrome and efficacy of a BCMA-CD3 bispecific antibody for the treatment of multiple myeloma in humanized mice
35. Abstract 3320: Humanized NSG-Tg(Hu-IL15) mice support preclinical immune-oncology efficacy for testing of NK cells based immunology
36. Innovations, challenges, and minimal information for standardization of humanized mice
37. Preclinical evaluation of efficacy and cytokine release of bispecific T cell engagers in humanized NSG mice
38. Abstract B72: Humanized NSG-Tg(Hu-IL15) mice support preclinical immune-oncology efficacy for testing of NK cell-based immunotherapy
39. Abstract 1070: Evaluation of human NK cell responses to PDX tumors in humanized NOD-scid IL2rgnull(NSG) mice expressing human IL15
40. Abstract 1070: Evaluation of human NK cell responses to PDX tumors in humanized NOD-scid IL2rgnull(NSG) mice expressing human IL15
41. Characterization of the Selective Indoleamine 2,3-Dioxygenase-1 (IDO1) Catalytic Inhibitor EOS200271/PF-06840003 Supports IDO1 as a Critical Resistance Mechanism to PD-(L)1 Blockade Therapy
42. Abstract 5676: Patient-derived tumor xenografts in humanized NSG-SGM3 mice: An improved immuno-oncology platform
43. Humanized mice in studying efficacy and mechanisms of PD‐1‐targeted cancer immunotherapy
44. Rapamycin reversal of VEGF-C–driven lymphatic anomalies in the respiratory tract
45. Abstract 2332: Patient-derived tumor xenografts in humanized NSG-SGM3 mice: a new immuno-oncology platform
46. Patient-derived tumor xenografts in humanized NSG-SGM3 mice: A new immuno-oncology platform.
47. Abstract LB-C01: Patient-derived tumor xenografts in humanized NSG-SGM3 mice: A new immuno-oncology platform
48. Neutrophil Dependence of Vascular Remodeling after Mycoplasma Infection of Mouse Airways
49. Pulmonary Lymphangiectasia Resulting From Vascular Endothelial Growth Factor-C Overexpression During a Critical Period
50. Plasticity of Button-Like Junctions in the Endothelium of Airway Lymphatics in Development and Inflammation
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.